Download PDF
Synlett 2010(9): 1367-1370  
DOI: 10.1055/s-0029-1219906
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of Novel 3-Amino(Hydroxy)methyl-l-fuco-Azafagomines as Leads for Selective Inhibitors of α-l-Fucosidases

Elena Moreno-Clavijoa, Ana T. Carmona*a, Antonio J. Moreno-Vargasa, Eleuterio Álvarezb, Inmaculada Robina*a
a Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Prof. García González 1, 41012 Seville, Spain
Fax: +34(954)624960; e-Mail: robina@us.es; e-Mail: anatere@us.es;
b Instituto de Investigaciones Químicas ‘Isla de la Cartuja’, CSIC-USE, Américo Vespucio 49, 41092 Sevilla, Spain
Further Information

Publication History

Received 8 February 2010
Publication Date:
10 May 2010 (online)

    Permissions and Reprints All articles of this category

Abstract

The synthesis of 3-substituted l-fuco-azafagomines from d-lyxose is reported. They represent the first example of aza-C-glycosides having a biimino (-NH-NH-) moiety. The key step of the synthesis is the introduction of the hydrazine moiety by reductive hydrazination of a 1-deoxy-ketohexose with tert-butyl carbazate. Their glycosidase inhibitory properties are also reported.

Key words

azasugars - glycosidases - fucosidase inhibitors - aza-fagomines - C-glycosides

    References and Notes

  • 1a Ma B. Simala-Grant JL. Taylor DE. Glycobiology  2006,  16:  158R 
    Google Scholar
  • 1b Vocadlo D. Davies GJ. Curr. Opin. Chem. Biol.  2008,  12:  539 
    Google Scholar
  • 1c Davies GJ. Ducros V M.-A. Varrot A. Zechel DL. Biochem. Soc. Trans.  2003,  31:  523 
    Google Scholar
  • 1d Benesova E. Markova M. Lipovova P. Kralova B. Chem. Listy  2005,  99:  324 
    Google Scholar
  • 2a Berteau O. Bielicki J. Kilonda A. Delphine Machy D. Anson DS. Kenne L. Biochemistry  2004,  43:  7881 
    Google Scholar
  • 2b Osanjo G. Dion M. Drone J. Solleux C. Tran V. Rabiller C. Tellier C. Biochemistry  2007,  46:  1022 
    Google Scholar
  • 3a Becker DJ. Lowe JB. Glycobiology  2003,  13:  41R 
    Google Scholar
  • 3b Compain P. Martin OR. Bioorg. Med. Chem.  2001,  9:  3077 
    Google Scholar
  • 3c Springer TA. Lasky LA. Nature (London)  1991,  349:  196 
    Google Scholar
  • 3d Ayude D. Fernández-Rodríguez J. Rodríguez-Berrocal FJ. Martínez-Zorzano VS. De Carlos A. Gil E. De la Cadena MP. Oncology  2000,  59:  310 
    Google Scholar
  • 3e Michalski JC. Klein A. Biochim. Biophys. Acta  1999,  1455:  69 
    Google Scholar
  • 3f Glick MC. Kothari VA. Liu A. Stoykova LI. Scanlin TF. Biochimie  2001,  83:  743 
    Google Scholar
  • 4a Kajimoto T. Node M. Curr. Top. Med. Chem.  2009,  9:  13 
    Google Scholar
  • 4b D’Alonzo D. Guaragna A. Palumbo G. Curr. Med. Chem.  2009,  16:  473 
    Google Scholar
  • 4c Gerber-Lemaire S. Juillerat-Jeanneret L. Mini-Rev. Med. Chem.  2006,  6:  1043 
    Google Scholar
  • 4d Robina I. Moreno-Vargas AJ. Carmona AT. Vogel P. Curr. Drug Metabol.  2004,  5:  329 
    Google Scholar
  • 5 Dubernet M. Defoin A. Tarnus C. Bioorg. Med. Chem. Lett.  2006,  61:  1172 
    Google Scholar
  • 6a Fleet GWJ. Namgoong SK. Barker C. Baines S. Jacob GS. Winchester B. Tetrahedron Lett.  1989,  30:  4439 
    Google Scholar
  • 6b Andrews DM. Bird MI. Cunningham MM. Ward P. Bioorg. Med. Chem. Lett.  1993,  3:  2533 
    Google Scholar
  • 6c Beacham AR. Smelt KH. Biggadike K. Britten CJ. Hackett L. Winchester BG. Nash RJ. Griffiths RC. Fleet GWJ. Tetrahedron Lett.  1998,  39:  151 
    Google Scholar
  • 7 Wu C.-Yi. Chang C.-F. Chen JS.-Y. Wong C.-H. Lin C.-H. Angew. Chem. Int. Ed.  2003,  42:  4661 
    CrossrefGoogle Scholar
  • 8a Davis BG. Tetrahedron: Asymmetry  2009,  20:  645 
    Google Scholar
  • 8b Iminosugars: From Synthesis to Therapeutic Applications   Compain P. Martin OR. Wiley-VCH; Weinheim: 2007. 
    Google Scholar
  • 8c Robina I. Vogel P. Synthesis  2005,  675 
    Google Scholar
  • 9a Ho C.-W. Lin Y.-N. Chang C.-F. Li S.-T. Wu Y.-T. Wu C.-Y. Chang C.-F. Liu S.-W. Li Y.-K. Lin C.-H. Biochemistry  2006,  45:  5695 
    Google Scholar
  • 9b Chang C.-F. Ho C.-W. Wu C.-Y. Chao T.-A. Wong C.-H. Lin C.-H. Chem. Biol.  2004,  11:  1301 
    Google Scholar
  • 10 Jensen HH. Jensen A. Hazzel RG. Bols M. J. Chem. Soc., Perkin Trans. 1  2002,  1190 
    CrossrefGoogle Scholar
  • 11a Hansen SU. Bols M. J. Chem. Soc., Perkin Trans. 2  2000,  665 
    Google Scholar
  • 11b Bülow A. Plesner IW. Bols M. J. Am. Chem. Soc.  2000,  122:  8567 
    Google Scholar
  • 11c Lohse A. Hardlei T. Jensen A. Plesner IW. Bols M. Biochem. J.  2000,  349:  211 
    Google Scholar
  • 11d Jensen HH. Lyngbye L. Jensen A. Bols M. Chem. Eur. J.  2002,  8:  1218 
    Google Scholar
  • 11e Sivertsen AC. Gasior M. Bjerring M. Hansen SU. López López O. Nielsen NC. Bols M. Eur. J. Org. Chem.  2007,  1735 
    Google Scholar
  • 11f G loster TM. Meloncelli P. Stick RV. Zechel D. Vasella A. Davies GJ. J. Am. Chem. Soc.  2007,  129:  2345 
    Google Scholar
  • 12 Jiang S. Rycroft AD. Singh G. Wang X.-Z. Wu Y.-L. Tetrahedron Lett.  1998,  39:  3809 ; compound 5 was reported but not characterized Characterization Data for 5 [α]D ²² -34.9 (c 0.74, CH2Cl2). ¹H NMR (300 MHz, CDCl3): δ = 7.71-7.65 (m, 4 H, Harom), 7.47-7.37 (m, 6 H, Harom), 4.82-4.78 (m, 2 H, H-2, H-3), 4.58 (td, 1 H, J 4,5a = J 4,5b = 6.4 Hz, J 4,3 = 2.6 Hz, H-4), 4.08-3.93 (m, 2 H, H-5a, H-5b), 1.36 [s, 6 H, C(CH3)2], 1.07 [s, 9 H, C(CH3)3] ppm. ¹³C NMR (75.4 MHz, CDCl3): δ = 173.9 (C=O), 135.8, 133.2, 133.0, 130.0, 128.0, 127.9 (C arom.), 114.2 [C(CH3)2], 79.5 (C-4), 76.2, 75.9 (C-2, C-3), 61.7 (C-5), 26.9 [C(CH3)3], 26.1 [C(CH3)2], 19.4 [C(CH3)3] ppm. MS (CI): m/z (%) = 427 (5) [M + H]+. HRMS (CI): m/z calcd for C24H31O5Si [M + H]+: 427.1941; found 427.1927
    CrossrefGoogle Scholar
  • 13 Jones NA. Jenkinson SF. Soengas R. Fanefjord M. Wormald MR. Dwek RA. Kiran GP. Devendar R. Takata G. Morimoto K. Izumoric K. Fleet GWJ. Tetrahedron: Asymmetry  2007,  18:  774 
    CrossrefGoogle Scholar
  • 17 This process of oxidation-isomerization has been previously studied for hydrazines and some examples are reported, see: Stone KJ. Greenberg MM. Blackstock SC. Berson JA. J. Am. Chem. Soc.  1989,  111:  3659 ; see also ref. 11a
    CrossrefGoogle Scholar
  • For the conditions used in the biological tests, see:
  • 19a Saul R. Chambers JP. Molyneux RJ. Elbein AD. Arch. Biochem. Biophys.  1983,  221:  593 
    Google Scholar
  • 19b Brandi A. Cicchi S. Cordero FM. Frignoli R. Goti A. Picasso S. Vogel P. J. Org. Chem.  1995,  60:  6806 
    Google Scholar
  • 20 Gerber-Lemaire S. Popowycz F. Rodriguez-Garcia E. Carmona Asenjo AT. Robina I. Vogel P. ChemBioChem  2002,  3:  466 
    CrossrefGoogle Scholar
14

Analytical Data for 8
[α]D ²5 -18.2 (c 1.19, CH2Cl2). ¹H NMR (500 MHz, DMSO-d 6): δ = 7.61-7.58 (m, 4 H, Harom), 7.48-7.38 (m, 6 H, Harom), 7.28-7.26 (m, 5 H, Harom), 5.18 (br d, 1 H, J NH,3 = 3.2 Hz, NH), 5.05 (d, 1 H, ² J H,H = 12.7 Hz, CH2 of Cbz), 5.02 (d, 1 H, CH2 of Cbz), 4.08 (dd, 1 H, J 5,4 = 5.5 Hz, J 5,6 = 4.8 Hz,
H-5), 3.97 (qd, 1 H, J 6,Me-6 = 7.2 Hz, H-6), 3.96 (t, 1 H, J 4,3 = 5.5 Hz, H-4), 3.65 (d, 2 H, J 1 ′ ,3 = 6.7 Hz, H-1′), 3.05 (m, 1 H, H-3), 1.34 (d, 3 H, Me-6), 1.33, 1.24 [2 s, 3 H each, C(CH3)2], 0.99 [s, 9 H, C(CH3)3] ppm. ¹³C NMR (125.7 MHz, DMSO-d 6): δ = 156.0 (C=O of Cbz), 136.7, 135.0, 132.7, 129.9, 128.2, 127.9, 127.8, 127.6, 127.3 (Carom), 108.0 [C(CH3)2], 72.6 (C-5), 70.8 (C-4), 66.2 (CH2 of Cbz), 63.7 (C-1′), 58.7 (C-3), 50.9 (C-6), 26.8, 25.7 [C(CH3)2], 26.5 [C(CH3)3], 18.7 [C(CH3)3], 15.9 (Me-6) ppm. MS-FAB: m/z (%) = 597 (40) [M + Na]+, 575 (8) [M + H]+. HRMS-FAB: m/z calcd for C33H42N2O5NaSi [M + Na]+: 597.2761; found: 597.2780.
Analytical Data for 9
[α]D ²6 -64.5 (c 0.82, CH2Cl2). ¹H NMR (500 MHz, DMSO-d 6): δ = 7.63-7.61 (m, 4 H, Harom), 7.49-7.30 (m, 11 H, Harom), 5.18 (br s, 2 H, CH2 of Cbz), 5.09 (br s, 1 H, NH), 4.56 (q, 1 H, J 6,Me-6 = 7.2 Hz, H-6), 3.99 (d, 1 H, J 5,4 = 5.0 Hz, H-5), 3.80 (dd, 1 H, J 4,3 = 9.4 Hz, H-4), 3.77 (dd, 1 H, ² J 1 ′ a,1 ′ b = 10.7 Hz, J 1 ′ a,3 = 3.0 Hz, H-1′a), 3.59 (dd, 1 H, J 1 ′ b,3 = 9.0 Hz, H-1′b), 2.89 (m, 1 H, H-3), 1.28 (d, 3 H,
Me-6), 1.20 [s, 6 H, C(CH3)2], 0.98 [s, 9 H, C(CH3)3] ppm. ¹³C NMR (125.7 MHz, DMSO-d 6): δ = 155.2 (C=O of Cbz), 136.9, 135.0, 132.6, 129.9, 128.2, 127.9, 127.8, 127.7, 127.1 (Carom), 108.0 [C(CH3)2], 75.0 (C-5), 70.0 (C-4), 66.3 (CH2 of Cbz), 63.3 (C-1′), 59.9 (C-3), 49.1 (C-6), 27.8, 26.3 [C(CH3)2], 26.5 [C(CH3)3], 18.7 [C(CH3)3], 16.1 (Me-6) ppm. MS-FAB: m/z (%) = 597 (50) [M + Na]+, 575 (10)
[M + H]+. HRMS-FAB: m/z calcd for C33H42N2O5NaSi [M + Na]+: 597.2761; found: 597.2802.

15

Crystal Data for 10
C24H30N2O7S, Mr = 490.56, orthorhombic, space group P2 1 2 1 2 1 (no. 19), a = 5.9856 (3) Å, b = 16.5688 (8) Å, c = 24.4976 (11) Å, V = 2429.5 (2) ų, Z = 4, ρ calcd  = 1.341 g cm-³, λ (Mo Kα1) = 0.71073 Å, F(000) = 1040, µ = 0.180 mm-¹, T = 173 (2) K, 34818 reflections measured, 4999 unique (R int = 0. 0847) which were used in all calculations. The final R1 = 0.0430 [I > 2σ(I)], wR2 = 0.1047 (all data). Flack parameter = -0.02 (8). Full crystallographic data for this structure have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication CCDC 764937. These data can obtained free of charge on application to CCDC, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 (1223)336033; or e-mail: deposit@ccdc.cam.ac.uk.

16

Analytical Data for 10
Mp 130-132 ˚C (EtOAc-PE). [α]D ²³ -6.4 (c 0.45, CH2Cl2). ¹H NMR (500 MHz, DMSO-d 6): δ = 7.76 (d, 2 H, ³ J H,H = 8.0 Hz, H-Ts), 7.46 (d, 2 H, H-Ts), 7.37-7.30 (m, 5 H, Harom), 5.17 (br s, 1 H, NH), 5.04 (d, 1 H, ² J H,H = 12.7 Hz, CH2 of Cbz), 5.01 (d, 1 H, CH2 of Cbz), 4.16 (t, 1 H, J 5,4 = J 5,6 = 5.5 Hz, H-5), 4.04-3.97 (m, 3 H, H-6, H-1′a, H-1′b), 3.83 (dd, 1 H, J 4,3 = 4.5 Hz, H-4), 3.10 (m, 1 H, H-3), 2.41 (s, 3 H, CH3 of Ts), 1.28 (d, 3 H, J 6,Me-6 = 7.0 Hz, Me-6), 1.31, 1.23 [2 s, 3 H each, C(CH 3 )2] ppm. ¹³C NMR (125.7 MHz, DMSO-d 6, 353 K): δ = 156.1 (C=O of Cbz), 145.1, 136.7, 132.0, 130.2, 128.3, 127.8, 127.6, 127.5 (Carom), 108.1 [C(CH3)2], 72.2 (C-5), 70.0, 69.9 (C-4, C-1′), 66.3 (CH2 of Cbz), 56.1 (C-3), 50.1 (C-6), 26.6, 25.6 [C(CH3)2], 21.1 (Me of Ts), 15.7 (Me-6) ppm. MS-FAB: m/z (%) = 513 (100) [M + Na]+, 491 (10) [M + H]+. HRMS-FAB: m/z calcd for C24H30N2O7SNa [M + Na]+: 513.1671; found: 513.1678. Anal. Calcd for C24H30N2O7S: C, 58.76; H, 6.16; N, 5.71; S, 6.54. Found: C, 58.75; H, 6.11; N, 5.82; S, 6.50.

18

Analytical Data for 3a
[α]D ²² -44.6 (c 0.6, MeOH). ¹H NMR (500 MHz, CD3OD): δ = 3.85-3.82 (m, 2 H, H-5, H-1′a), 3.74 (dd, 1 H, ² J 1 ′ b,1 ′ a = 11.6 Hz, J 1 ′ b,3 = 5.5 Hz, H-1′b), 3.63 (dd, 1 H, J 4,3 = 10.3 Hz, J 4,5 = 2.8 Hz, H-4), 3.35 (qd, 1 H, J 6,Me-6 = 6.8 Hz, J 6,5 = 1.2 Hz, H-6), 3.24 (ddd, 1 H, J 3,1 ′ a = 2.9 Hz, H-3), 1.28 (d, 3 H, Me-6) ppm. ¹³C NMR (125.7 MHz, CD3OD):
δ = 69.6 (C-5), 68.1 (C-4), 60.1 (C-1′), 58.0 (C-6), 57.5 (C-3), 14.0 (Me-6) ppm. MS (CI): m/z (%) = 163 (40) [M + H]+. HRMS (CI): m/z calcd for C6H15N2O3 [M + H]+: 163.1083; found: 163.1083.
Analytical Data for 15
[α]D ²² -12.3 (c 0.85, MeOH). ¹H NMR (500 MHz, CD3OD): δ = 3.85 (dd, 1 H, ² J 1 ′ a,1 ′ b = 11.5 Hz, J 1 ′ a,3 = 3.7 Hz, H-1′a), 3.81 (dd, 1 H, J 4,3 = 7.4 Hz, J 4,5 = 2.9 Hz, H-4), 3.77 (dd, 1 H, J 1 ′ b,3 = 6.9 Hz, H-1′b), 3.71 (m, 1 H, H-5), 3.51 (qd, 1 H, J 6,Me-6 = 6.9 Hz, J 6,5 = 5.4 Hz, H-6), 3.36 (td, 1 H, H-3), 1.34 (d, 3 H, Me-6) ppm. ¹³C NMR (125.7 MHz, CD3OD): δ = 70.1 (C-5), 65.4 (C-4), 60.5 (C-3), 60.2 (C-1′), 56.6 (C-6), 13.2 (Me-6) ppm. MS (CI): m/z (%) = 163 (65) [M + H]+. HRMS (CI): m/z calcd for C6H15N2O3 [M + H]+: 163.1083; found: 163.1087.